BCL1, a murine model for chronic lymphocytic leukemia: use of the surface immunoglobulin idiotype for the detection and treatment of tumor.

PubWeight™: 1.27‹?› | Rank: Top 10%

🔗 View Article (PMID 94899)

Published in Immunol Rev on January 01, 1979

Authors

K A Krolick, P C Isakson, J W Uhr, E S Vitetta

Articles citing this

Cell growth cycle block of T cell hybridomas upon activation with antigen. J Exp Med (1987) 2.30

Induction of proliferation and differentiation of neoplastic B cells by anti-immunoglobulin and T-cell factors. Proc Natl Acad Sci U S A (1981) 1.12

Immunoregulation of murine myeloma in vitro. II. Suppression of MOPC-315 immunoglobulin secretion and synthesis by idiotype-specific suppressor T cells. J Exp Med (1982) 1.03

Acquisition of cell surface IgD after in vitro culture of neoplastic B cells from the murine tumor BCL1. J Exp Med (1980) 1.01

In vivo therapy of a murine B cell tumor (BCL1) using antibody-ricin A chain immunotoxins. J Exp Med (1982) 0.96

A monoclonal antibody against a murine CD38 homologue delivers a signal to B cells for prolongation of survival and protection against apoptosis in vitro: unresponsiveness of X-linked immunodeficient B cells. Immunology (1995) 0.94

Possible role of anti-idiotypic antibodies in the induction of tumor immunity. J Clin Invest (1987) 0.91

Concomitant cellular and humoral expression of a regulatory cross-reactive idiotype in acute Schistosoma japonicum infection. Infect Immun (1986) 0.85

Demonstration and immunochemical characterization of natural, autologous anti-idiotypic antibodies throughout the course of experimental syphilis. Infect Immun (1990) 0.82

Cytotoxic T cells specific for antigens expressed on surface immunoglobulin-positive cells. J Exp Med (1981) 0.82

Consumption of monoclonal anti-idiotypic antibody by neoplastic B lymphocytes: a guide for immunotherapy. Br J Cancer (1984) 0.82

Syngeneic antiidiotypic immune responses to a B cell lymphoma. Comparison between heavy chain hypervariable region peptides and intact Ig as immunogens. J Exp Med (1985) 0.78

BCL1, a murine model of prolymphocytic leukemia. I. Effect of splenectomy on growth kinetics and organ distribution. Am J Pathol (1981) 0.77

Mechanisms of tumour cell escape encountered in treating lymphocytic leukaemia with anti-idiotypic antibody. Br J Cancer (1984) 0.77

Secretion of idiotypic IgM by the mouse B-cell leukaemia (BCL1) occurs spontaneously in vitro and in vivo. Immunology (1985) 0.77

The Role of Regulatory B Cell-Like Malignant Cells and Treg Cells in the Mouse Model of BCL1 Tumor Dormancy. PLoS One (2016) 0.75

BCL1, a murine model of prolymphocytic leukemia. II. Morphology and ultrastructure. Am J Pathol (1981) 0.75

Articles by these authors

Regulatory effect of antibody on the immune response. Adv Immunol (1968) 6.03

Cell surface immunoglobulin. II. Isolation and characterization of immunoglobulin from mouse splenic lymphocytes. J Exp Med (1971) 5.80

Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature (1988) 5.56

Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature (1997) 5.11

Detection and characterization of carcinoma cells in the blood. Proc Natl Acad Sci U S A (1998) 4.76

The carriage of immunological memory by small lymphocytes in the rat. J Exp Med (1966) 4.73

Increased expression of Ia antigens on resting B cells: an additional role for B-cell growth factor. Proc Natl Acad Sci U S A (1984) 4.62

T cell-derived B cell differentiation factor(s). Effect on the isotype switch of murine B cells. J Exp Med (1982) 4.51

Serological, biochemical, and functional identity of B cell-stimulatory factor 1 and B cell differentiation factor for IgG1. J Exp Med (1985) 4.47

Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA (1999) 4.25

Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). J Med Chem (1997) 4.22

Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci U S A (1994) 4.15

Passive sensitization of lymphocytes and macrophages by antigen-antibody complexes. Proc Natl Acad Sci U S A (1965) 3.83

Polyribosomal synthesis and assembly of the H and L chains of gamma globulin. Proc Natl Acad Sci U S A (1966) 3.53

Immunoglobulin-receptors revisited. Science (1975) 3.38

Biochemical evidence linking the GIX thymocyte surface antigen to the gp69/71 envelope glycoprotein of murine leukemia virus. J Exp Med (1975) 3.31

Cell surface immunoglobulin. XI. The appearance of an IgD-like molecule on murine lymphoid cells during ontogeny. J Exp Med (1975) 3.26

Lymphokine-mediated regulation of the proliferative response of clones of T helper 1 and T helper 2 cells. J Exp Med (1988) 3.16

Primary-type antibody response in vitro. Science (1966) 2.82

Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci U S A (1998) 2.71

Delayed hypersensitivity. Physiol Rev (1966) 2.64

Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet (2000) 2.63

Cell surface immunoglobulin. IV. Distribution among thymocytes, bone mrrow cells, and their derived populations. J Exp Med (1972) 2.50

B-cell growth factor (B-cell growth factor I or B-cell-stimulating factor, provisional 1) is a differentiation factor for resting B cells and may not induce cell growth. Proc Natl Acad Sci U S A (1985) 2.41

Functional and ontogenetic analysis of murine CD45Rhi and CD45Rlo CD4+ T cells. J Immunol (1990) 2.41

Isolation of heavy and light chains of immunoglobulin from the surfaces of lymphoid cells. J Immunol (1971) 2.35

Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia, and interleukin 6 production in vivo. J Exp Med (1996) 2.28

Organization of the immune response genes. Science (1979) 2.18

Vascular leak syndrome: a side effect of immunotherapy. Immunopharmacology (1997) 2.07

Mechanisms underlying binding of immune complexes to macrophages. J Exp Med (1971) 2.00

Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. J Clin Invest (1996) 1.98

Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc (1999) 1.96

The kinetics of antibody formation. Prog Allergy (1967) 1.92

The differential expression of homing and adhesion molecules on virgin and memory T cells in the mouse. Cell Immunol (1991) 1.88

Selective killing of normal or neoplastic B cells by antibodies coupled to the A chain of ricin. Proc Natl Acad Sci U S A (1980) 1.85

B cell-stimulatory factor 1 (BSF-1) promotes growth of helper T cell lines. J Exp Med (1986) 1.82

Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer. Int J Oncol (2002) 1.81

Redesigning nature's poisons to create anti-tumor reagents. Science (1987) 1.81

Association of a beta2-microglobulin-like subunit with H-2 and TL alloantigens on murine thymocytes. J Immunol (1975) 1.79

Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum (1998) 1.79

The response of lymphocytes from non-immunized humans to antigen-antibody complexes. Clin Exp Immunol (1968) 1.79

Synthesis of germ-line gamma 1 immunoglobulin heavy-chain transcripts in resting B cells: induction by interleukin 4 and inhibition by interferon gamma. Proc Natl Acad Sci U S A (1989) 1.78

Immunoglobulin synthesis and secretion. II. Radioautographic studies of sites of addition of carbohydrate moieties and intracellular transport. J Cell Biol (1970) 1.78

Cyclooxygenase-2 inhibition prevents delayed death of CA1 hippocampal neurons following global ischemia. Proc Natl Acad Sci U S A (1998) 1.77

Regulation of antibody formation by serum antibody. I. Removal of specific antibody by means of immunoadsorption. J Exp Med (1969) 1.76

Structural similarities between a product of the T/t-locus isolated from sperm and teratoma cells, and H-2 antigens isolated from splenocytes. Proc Natl Acad Sci U S A (1975) 1.76

The protein products of the murine 17th chromosome: genetics and structure. Adv Immunol (1978) 1.76

Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase. Biochem J (1995) 1.74

Induction of B cell differentiation by T cell factors. I. Stimulation of IgM secretion by products of a T cell hybridoma and a T cell line. J Immunol (1981) 1.73

Activation of antigen-specific B cells: role of T cells, cytokines, and antigen in induction of growth and differentiation. Proc Natl Acad Sci U S A (1983) 1.73

The relationship between surface immunoglobulin isotype and immune function of murine B lymphocytes. I. Surface immunoglobulin isotypes on primed B cells in the spleen. J Exp Med (1977) 1.71

Regulation of antibody formation by serum antibody. II. Removal of specific antibody by means of exchange transfusion. J Exp Med (1970) 1.70

Cell surface immunoglobulin. X. Identification of an IgD-like molecule on the surface of murine splenocytes. J Exp Med (1974) 1.70

Synthesis of excess light chains of gamma globulin by rabbit lymph node cells. Nature (1966) 1.66

Immunotoxins: a new approach to cancer therapy. Science (1983) 1.65

T-cell-derived lymphokines that induce IgM and IgG secretion in activated murine B cells. Immunol Rev (1984) 1.65

Kinetic basis for selective inhibition of cyclo-oxygenases. Biochem J (1999) 1.64

Highly purified CD25- resting T cells cannot be infected de novo with HIV-1. Proc Natl Acad Sci U S A (1997) 1.62

Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin Cancer Res (1995) 1.62

Expression of murine leukemia virus envelope glycoprotein gp69/71 on mouse thymocytes. Evidence for two structural variants distinguished by presence vs. absence of GIX antigen. J Exp Med (1975) 1.62

IgD and B cell differentiation. Immunol Rev (1977) 1.59

Clonal analysis of B cells induced to secrete IgG by T cell-derived lymphokine(s). J Exp Med (1984) 1.58

B-cell tolerance. II. Trinitrophenyl human gamma globulin-induced tolerance in adult and neonatal murine B cells responsive to thymus-dependent and independent forms of the same hapten. J Exp Med (1977) 1.57

Cell surface immunoglobulin. XX. Antibody responsiveness of subpopulations of B lymphocytes bearing different isotypes. J Exp Med (1977) 1.57

Lymphokine-induced IgM secretion by clones of neoplastic B cells. Nature (1983) 1.56

Cell surface immunoglobulin. V. Release from murine splenic lymphocytes. J Exp Med (1972) 1.56

The cytophilic activity of human immunoglobulins. J Immunol (1970) 1.55

T cell-derived B cell growth and differentiation factors. Dichotomy between the responsiveness of B cells from adult and neonatal mice. J Exp Med (1983) 1.54

Characterization of the physical interaction between antigen-specific B and T cells. J Immunol (1986) 1.53

Cyclooxygenases and the central nervous system. Prostaglandins (1997) 1.53

Immunoglobulins, antibodies and the bursa of Fabricus: induction of agammaglobulinemia and the loss of all antibody-forming capacity by hormonal bursectomy. J Immunol (1969) 1.52

Neoplastic B cells as targets for antibody-ricin A chain immunotoxins. Immunol Rev (1982) 1.52